Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A neuropsychological profile for high-grade primary central nervous system neuroendocrine tumor (CNS NET): A single-case study.
Clin Neuropsychol
January 2025
Department of Neurology, Emory University, Atlanta, GA, USA.
Neuroendocrine tumors (NETs) are neoplasms that primarily occur in the lungs, appendix, small intestine, pancreas, and rectum, and typically metastasize to the liver or lymph nodes. However, in rare cases NETs can originate in the central nervous system (CNS). Understanding primary CNS NET neuropsychological manifestations aids in recommendations for neurocognitive follow-up, treatment and lifestyle planning, and future research.
View Article and Find Full Text PDFSinonasal Neuroendocrine Carcinoma: A Case report.
Indian J Otolaryngol Head Neck Surg
December 2023
Gauhati Medical College and Hospital, Guwahati, Assam India.
Neuroendocrine carcinoma are rare tumor which begin in specialized cells called neuroendocrine cells. It can occur anywhere in the body. Most neuroendocrine tumors occur in the lungs, appendix, small intestine, rectum and pancreas.
View Article and Find Full Text PDFCracking the Code of a Rare Colonic Mesentery Gastrointestinal Neuroendocrine Tumor Disguised as Chronic Gastroenteritis: The Critical Art of Timely Detection.
Cureus
September 2023
Radiology, One Brooklyn Health, Brooklyn, USA.
Neuroendocrine tumors (NETs) typically present in the setting of metastasis from other solid organs and are considered late manifestations of the disease. Therefore, primary tumors are extremely rare. NETs of the colonic mesentery occur more than 70% of the time in the appendix, small intestine, and rectum.
View Article and Find Full Text PDFEfficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
Clin Cancer Res
May 2020
Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.
Purpose: KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from patients with previously treated advanced well-differentiated neuroendocrine tumors (NET).
View Article and Find Full Text PDFEZH2 Expression in Intestinal Neuroendocrine Tumors.
Appl Immunohistochem Mol Morphol
October 2019
Department of Surgical, Medical, Molecular Pathology and Critical Area.
Neuroendocrine tumors (NETs) arise from the cells present throughout the diffuse endocrine system. These neoplasms were previously regarded as rare, but in fact are increasing in incidence (3.65/100 000 individuals/y).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!